Clinical Trials Browser

Advanced Microsatellite Stable Colorectal Cancer

Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma

Carcinoma, Hepatocellular

Colorectal Neoplasms

Stomach Neoplasms

Brain Neoplasms

Colorectal Neoplasms

Uterine Cervical Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

Colorectal Neoplasms

Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

Ras-mutated Metastatic Colorectal Cancer

Advanced Gynecological Malignancies

Colorectal Neoplasms

Lung Diseases, Interstitial

Diabetes Mellitus, Insulin-Dependent, 12, Adenocarcinoma of Lung

Carcinoma, Hepatocellular

Colorectal Neoplasms

Colorectal Neoplasms

Rectal Neoplasms Malignant

Colorectal Neoplasms

Ovarian Neoplasms

Colorectal Neoplasms

Medulloblastoma

Colorectal Neoplasms

Ovarian Neoplasms, Recurrence

Colorectal Neoplasms

Colorectal Neoplasms

Platinum-resistant Recurrent Ovarian Cancer (PROC)

Advanced Solid Tumor

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Appendiceal Neoplasms, Colorectal Neoplasms

Colorectal Neoplasms

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Colonic Neoplasms

Colorectal Neoplasms

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasm Metastasis

Breast Cancer With Brain Metastasis

Disease, Colorectal Neoplasms

Ovarian Neoplasms

Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Hepatocellular

Colorectal Neoplasms

Advanced Ovarian Cancer

Clinical Trials

Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma

A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma

A Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid Tumors

Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer

JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer

MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)

SYS6090 Combination Therapy in Advanced Lung Cancer

A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer

QLS5132 Combination Therapy in Advanced Solid Tumors

FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors

ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer

Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

PHOENIX

A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma

A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond.

LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation

CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer

ROMANCE - GOIM

To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer

IBI363 Plus Bevacizumab With or Without Nab-Paclitaxel for Second-Line Treatment of Advanced Gastric Cancer

Clinical Study on the Use of Huaier Granules for the Treatment of Proteinuria Related to Bevacizumab and Anlotinib in Lung Cancer Patients

COLIBRI-GI

PNOC044

ARIEL-ENGIC

TROY

Gossypol Acetate + FOLFIRI + Bev in mCRC With TP53-Mutant and LRPPRC Positive

A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation

Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combined With Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer

A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors

Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma

Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma

Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial

Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority Trial

Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer

HOFIBREN

REFISH

Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer

A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy

THUMB

SMARTi-RC01

Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer

ANGELICA

QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC

A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)

A Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal Cancer

Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein Marker